3DSecret is developing microfluidic platforms to isolate circulating tumor cells and culture them into 3D spheroids for multi-parametric analysis. This technology aims to uncover stochastic patterns in metastatic breast cancer, enabling precise predictions of cancer evolution at the single-cell level.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metastatic breast cancer exhibits stochastic patterns at the single-cell level, making it difficult to predict cancer evolution and hindering the development of effective treatments. Current methods for analyzing circulating tumor cells (CTCs) often lack the ability to culture them into 3D spheroids for comprehensive multi-parametric analysis.
Solution
3DSecret is developing microfluidic platforms designed to isolate circulating tumor cells (CTCs) from patient samples and culture them into 3D spheroids. This enables multi-parametric analysis of the CTCs, providing insights into the stochastic patterns driving metastatic breast cancer. By analyzing CTCs at the single-cell level, 3DSecret aims to improve the prediction of cancer evolution. The platform integrates microfluidics, nanotechnology, genomics, and AI to provide a comprehensive solution for CTC analysis. The resulting data can be used to identify potential therapeutic targets and develop personalized treatment strategies.
Target Audience
The primary target audience includes cancer researchers, oncologists, and pharmaceutical companies involved in developing new treatments for metastatic breast cancer.
Features
- Microfluidic platform for efficient isolation of circulating tumor cells (CTCs)
- 3D spheroid culture of CTCs to mimic the tumor microenvironment
- Multi-parametric analysis of CTCs at the single-cell level
- Integration of genomics and AI for comprehensive data analysis